In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager ...
BOSTON, April 16, 2026 (GLOBE NEWSWIRE)-- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study1 evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, versus standard available ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
BildderFrau on MSN
So häkelst du dir deine alten Hosen wieder schön: 3 tolle Ideen
Hosen, die im Schrank versauern, haben jetzt ein Comeback verdient! Wir zeigen dir einfache Upcycling-Ideen, um alte Jeans zu verlängern, zu verbreitern oder sogar in einen Rock zu verwandeln.
ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...
Approved CD20×CD3 bispecifics (epcoritamab, glofitamab, mosunetuzumab) deliver meaningful ORR/CR in heavily pretreated DLBCL, but PFS remains modest, motivating combination strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results